Harris Todd

CEO Harris Todd sells 62,720 shares for $1.7M across three days as TYRA stock near 52-week high; company unprofitable with -$18.7M annual net income

Harris Todd, President and CEO of Tyra Biosciences, executed 3 separate sales totaling 62,720 shares (62.7K shares) for $1,711,247.19 ($1.7M) at a blended average price of $27.28 between October 16–21, 2024. The stock is currently at $28.16, only -0.7% from its 52-week high of $28.37, and has appreciated 15.6% over the prior 30 days and 34.2% over 90 days. Todd's post-transaction holdings of 1,355,927 shares (1.36M shares) represent a -4.4% reduction from his prior position of 1,418,647 shares (1.42M shares). Against this backdrop of strong recent price momentum near all-time highs, the company reported a full fiscal year net income of -$18,702,000.00 ($-18.7M), making it unprofitable. The timing of the sales at price levels near the 52-week high, combined with the company's negative earnings, presents a material signal that investors should monitor, particularly regarding whether this pattern continues or extends.

CEO Harris Todd sells 58,726 shares at blended avg $25.77, raising $1.5M; stock near 52-week high; prior same-ticker sales showed mixed 90-day timing.

Harris Todd, President and CEO, executed 6 separate sales totaling 58,726 shares for $1,513,271.36 over October 15–17, 2024, at prices ranging from $24.31 to $26.98 and a blended average price of $25.77. The current stock price is $25.98, placing the sales at approximately the 52-week high (+0.0% from that threshold). Following the sales, Todd retains 1,418,647 shares, a reduction of 4.0% from his pre-transaction holdings. His prior three sales at TYRA show a timing pattern of 0 of 3 well-timed at the 90-day mark, with 90-day returns of +5.2%, +12.7%, and +8.7% respectively—all positive, meaning prior sales preceded stock appreciation rather than decline. The company remains unprofitable with net income of $-18,702,000.00 over its most recent fiscal year, while the stock has posted strong recent momentum (+16.2% over 30 days, +31.7% over 90 days). The filing presents a liquidation near historical highs against a backdrop of operating losses and a pattern of missed bearish timing at this ticker.